Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345828 | 0.81 | KCNN4 (0.58) | KCNN4TSHRCYP1A2ALDH1A1TAAR1 | |
| SCHEMBL1436199 | 0.81 | KCNN4 (0.58) | KCNN4TSHRCYP1A2ALDH1A1TAAR1 | |
| Hydrochloric Acid SCHEMBL9576091 | 0.79 | KCNN4 (0.55) | KCNN4TSHRCYP1A2ALDH1A1TAAR1 | |
| SCHEMBL4690524 | 0.77 | KCNN4 (0.52) | KCNN4TSHRCYP1A2ALDH1A1TAAR1 | |
| SCHEMBL6930353 | 0.77 | KCNN4 (0.52) | KCNN4TSHRCYP1A2ALDH1A1TAAR1 | |
| SCHEMBL2005276 | 0.77 | KCNN4 (0.52) | KCNN4TSHRCYP1A2ALDH1A1TAAR1 | |
| SCHEMBL27947103 | 0.76 | KCNN4 (0.69) | KCNN4TSHRCYP1A2ALDH1A1TAAR1 | |
| SCHEMBL15366 | 0.76 | KCNN4 (0.69) | KCNN4TSHRCYP1A2ALDH1A1TAAR1 | |
| SCHEMBL6145 | 0.75 | KCNN4 (0.58) | KCNN4TSHRALDH1A1TAAR1MAPK1 | |
| Triphenylmethanamine SCHEMBL27516266 | 0.75 | KCNN4 (0.88) | KCNN4TSHRCYP1A2ALDH1A1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101657437-B | Novel method for preparing levocetirizine and intermediate thereof | KRKA TOVARNA ZDRAVIL D D NOVO MESTO | 2013-09-25 | — | — | CN | disclosed |
| CN-101657437-A | Novel method for preparing levocetirizine and intermediate thereof | KRKA TORVARNA ZDRAVIL D D NOVO | 2010-02-24 | — | — | CN | disclosed |
| US-7521469-B2 | Phosphinic amino acid compounds | LES LABORATOIRES SERVIER (FR) | 2009-04-21 | — | — | US | disclosed |
| US-20080153890-A1 | Phosphinic Amino Acid Compounds | LES LABORATOIRES SERVER (FR) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153890-A1 | Phosphinic Amino Acid Compounds | NPR1, NPPA, AADAT | KCNN4 1169/4885TSHR 1322/4885CYP1A2 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.